Investigational new drugs for allergic rhinitis

Peter A. Ricketti, Sultan Alandijani, Chen Hsing Lin, Thomas B. Casale

Research output: Contribution to journalReview article

15 Scopus citations

Abstract

Introduction: Allergic rhinitis (AR) is a multifactorial disease characterized by paroxysmal symptoms of sneezing, rhinorrhea, postnasal drip and nasal congestion. For over a century, subcutaneous allergen immunotherapy (SCIT) has been recognized as the most effective therapy to date that may modify the underlying disease course and provide long-term benefits for individuals refractory to pharmacotherapy. However, over the past 25 years, there has been substantial growth in developing alternative therapies to traditional SCIT. Areas covered: This article will review the most current literature focusing on advancements of AR therapies. Novel AR therapies that are currently under investigation include: the addition of omalizumab, an anti-immunoglobulin E (IgE) monoclonal antibody (mAb), to SCIT; altering the method of delivery of allergen immunotherapy (AIT) including sublingual (SLIT), epicutaneous (EIT), intralymphatic (ILIT), intranasal (INIT) and oral mucosal immunotherapy (OMIT); use of capsaicin spray; novel H3 and H4 antihistamines; activation of the innate immune system through Toll-like receptor agonists; and the use of chemically altered allergens, allergoids, recombinant allergens and relevant T-cell epitope peptides to improve the efficacy and safety of AIT. Expert opinion: These promising novel therapies may offer more effective and/or safer treatment options for AR patients, and in some instances, induce immunologic tolerance.

Original languageEnglish (US)
Pages (from-to)279-292
Number of pages14
JournalExpert Opinion on Investigational Drugs
Volume26
Issue number3
DOIs
StatePublished - Mar 4 2017

Keywords

  • Allergic rhinitis
  • EIT
  • ILIT
  • INIT
  • OMIT
  • SCIT
  • SLIT
  • TLR agonists
  • allergoids
  • capsaicin
  • novel antihistamines
  • omalizumab
  • peptides
  • recombinant allergens

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Investigational new drugs for allergic rhinitis'. Together they form a unique fingerprint.

Cite this